Clinical trials: Chemotherapy Induced Thrombocytopenia
Purpura, Thrombocytopaenic, Idiopathic
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems.
- Trial name
- NCT00359463
- Testing
- eltrombopag
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Thrombocytopenia
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 to prevention chemotherapy-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood.
- Trial name
- NCT05554913
- Testing
- QL0911
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy-Induced Thrombocytopenia
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of…
- Trial name
- NCT05261646
- Testing
- Hetrombopag
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Severe Thrombocytopenia
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
This is an open-label study in which oprelvekin will be administered for the prevention of severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting stable) in adults with cancer who are taking…
- Trial name
- NCT00886743
- Testing
- oprelvekin
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Chemotherapy-induced Thrombocytopenia
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
This phases Ⅲ trials is divided into two stages,Ⅲa and Ⅲb.The aim of Ⅲa is to evaluate the optimal dosing dose of genetically modified recombinant human IL-11 (mIL-11) in a multicenter randomized self-control trial involving 60…
- Trial name
- NCT01663441
- Testing
- NL201, rhIL-11
- Where
- 5 sites in China
- Volunteers
- 62 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Thrombocytopenia
Thrombocytopenia Induced by Chemotherapy
Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia.
- Trial name
- papayaleaf (NCT03567798)
- Testing
- UPLAT
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Socrates School Of Health
Chemotherapy-induced Thrombocytopenia
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung…
- Trial name
- NCT03471078
- Testing
- Avatrombopag
- Where
- 55 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Sobi, Inc.
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
- Trial name
- NCT05864014
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy-induced Thrombocytopenia
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 in Chemotherapy- Induced Thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of chemotherapy.
- Trial name
- NCT05851027
- Testing
- QL0911
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
- Conditions
- Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Cancer
- Trial name
- NCT00283439
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura
A Study of PN20 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are: Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a…
- Trial name
- NCT06523088
- Testing
- PN20
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Thrombocytopenia
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
Purpose: To evaluate the efficacy and safety of rHuTPO/rHuIL-11 in the treatment for chemotherapy-induced thrombocytopenia in patients with NSCLC receiving gemcitabine and cisplatin or carboplatin chemotherapy.
- Trial name
- NCT02344979
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy-Induced Thrombocytopenia
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two…
- Trial name
- NCT01345214
- Testing
- ONO-7746
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 17 people
- Sponsor
- Ono Pharma USA Inc
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Chemotherapy-induced Thrombocytopenia
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include…
- Trial name
- NCT03049774
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Thrombocytopaenia
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with…
- Trial name
- NCT00102726
- Testing
- SB497115
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 183 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
- Trial name
- NCT03937154
- Testing
- Romiplostim
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 145 people
- Sponsor
- Amgen